<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549665</url>
  </required_header>
  <id_info>
    <org_study_id>MP-CR-008</org_study_id>
    <nct_id>NCT01549665</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease</brief_title>
  <acronym>GVHD-MSC</acronym>
  <official_title>Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medipost Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graft-versus-host-disease (GVHD) is a major complication following allogeneic hematopoietic&#xD;
      stem cell transplantation (allo-HSCT) which may cause acute life-threatening morbidity or&#xD;
      chronic disabilities. Although corticosteroid, the primary agent to treat GVHD, may be&#xD;
      effective for some patients, outcomes of those who are refractory to corticosteroid are&#xD;
      dismal. Secondary agents can be used for steroid-refractory cases; however, their efficacy is&#xD;
      variable and usually limited. The quality of life issue of chronic GVHD is especially&#xD;
      important for pediatric survivors who have longer life expectancy than adults. Many in-vitro&#xD;
      and in-vivo data support immunoregulatory properties of mesenchymal stem cells(MSCs)and&#xD;
      possibilities of treating diseases caused by immune dysregulation such as GVHD. Recent data&#xD;
      revealed that bone marrow-derived MSCs were very useful to treat steroid-refractory acute&#xD;
      GVHD, which led to improved overall survival compared with controls. More recently, a number&#xD;
      of reports suggest MSCs may also be useful in treating chronic GVHD as well as acute GVHD. It&#xD;
      has been also reported that third party MSCs are also useful as well as those from autologous&#xD;
      or HLA-matched donors. The investigator recently demonstrated that MSCs obtained from&#xD;
      umbilical cord blood (UCB) have similar immunosuppressive properties as bone marrow-MSCs.&#xD;
      UCB-MSCs can be obtained without doing any harm to donors that it may be more appropriate&#xD;
      source of MSCs than bone marrow for off-the-shelf use. However, little is known about the&#xD;
      safety and efficacy of UCB-MSCs in treating GVHD. Therefore, the investigator designed this&#xD;
      study to evaluate the safety and efficacy of UCB-MSCs in treating pediatric patients with&#xD;
      steroid-refractory acute or chronic GVHD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of UCB-MSC in SR-GVHD</measure>
    <time_frame>180 days</time_frame>
    <description>Vital sign&#xD;
Physical examination&#xD;
ECOG performance status&#xD;
Mixed Lymphocyte Reaction(MLR)&#xD;
Adverse effects related to infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete, Partial Response Rate at 28 and 180 Days in participants with SR-GVHD treated with UCB-MSC</measure>
    <time_frame>180 Days</time_frame>
    <description>Complete Response(CR) rate(%) = (Number of CR/Number of Participants)x100&#xD;
Partial Response(PR)rate(%) = (Number of PR/Number of Participants)x100</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Graft-Versus-Host Disease</condition>
  <condition>GVHD</condition>
  <condition>Allogeneic Hematopoietic Transplant</condition>
  <condition>Disorder Related to Transplantation</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human umbilical cord blood-derived mesenchymal stem cells</intervention_name>
    <description>1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.</description>
    <other_name>PROMOSTEMÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Steroid-refractory acute or chronic graft-versus-host-disease&#xD;
&#xD;
          -  Acquisition of consent form&#xD;
&#xD;
          -  0-30 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Withdrawal from the study&#xD;
&#xD;
          -  Progression of underlying hematologic diseases&#xD;
&#xD;
          -  Severe adverse effects related to the investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pediatrics, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Hoe Koo, MD, PhD</last_name>
      <phone>+82-2-3410-3524</phone>
      <email>hhkoo.koo@samsung.com</email>
    </contact>
    <contact_backup>
      <last_name>Keon Hee Yoo, M.D., Ph.D.</last_name>
      <phone>+82-2-3410-3532</phone>
      <email>hema2170@skku.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hong Hoe Koo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Hong Hoe Koo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Graft-Versus-Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Allogeneic hematopoietic transplant</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Unrelated Donors</keyword>
  <keyword>Cord Blood Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

